In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

Novel circulating biomarkers predicting atherosclerosis, Science in Practice from early detection to guided treatment

ESC Congress Report

•    Biomarkers are needed for diagnosis, prediction and assessment of treatment efficacy in cardiovascular diseases.


The session provided insight in the research field  of  innovation in biomarker discovery.

A nice example of fine-tuning the use of miRNAs in diagnosis of atherosclerotic disease was provided by Manuel Mayr (London, GB). He showed that the use of aspirin or heparin strongly affects miRNA clusters that are associates with platelet activation. When these medications were administered, variability between patients vanished.

M.  Ala-Korpela (Oulu, F) discussed the upcoming potential of metabolomics. Large numbers of metabolites can be measured in a standardised fashion using NMR and /or Mass spectrometry (MS). The speaker noted that within 5 years, the field of diagnostics would be dominated by metabolite measurements. This expectation, however, merits careful consideration since NMR and MS are not routinely applied technologies in a daily clinical setting, where there is a more urgent need for point of care tests. In addition, metabolites are strongly influenced by age, gender and other risk factors which may limit general applicability.

The next speaker, J. Tunon Fernandez (Madrid, ES), highlighted the current applications of proteomics technology in the field of cardiovascular disease. Examples were given where the following sample types were successfully analysed: blood cells, plaques, serum/plasma and the secretome. The latter (secretome from lesions in a culture setting) was mainly applied for discovery of plaque based markers.

The final presentation by S. Trimarchi (San Donato Milanese, IT) summarised the use of biomarkers of ascending and descending aneurysm formation.

This was an interesting session highlighting the still existing need for new biomarkers, not just form routine diagnostics but also for stratified applications.




Novel circulating biomarkers predicting atherosclerosis, Science in Practice from early detection to guided treatment

The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.